Investigating the effects of dendrobine on fibrosis and inflammation in orbital fibroblasts of thyroid-associated ophthalmopathy via network pharmacology, molecular docking, and transcriptomics
- PMID: 40544935
- DOI: 10.1016/j.ejphar.2025.177871
Investigating the effects of dendrobine on fibrosis and inflammation in orbital fibroblasts of thyroid-associated ophthalmopathy via network pharmacology, molecular docking, and transcriptomics
Abstract
This study aims to evaluate the effects and mechanisms of dendrobine against thyroid-associated ophthalmopathy (TAO). Potential targets of dendrobine and TAO were selected to construct a protein-protein interaction network, elucidating the potential mechanisms of dendrobine against TAO. The potential mechanisms systematically were verified by molecular docking, transcriptomics and in vitro experiments. Orbital fibroblasts (OFs) were isolated from orbital decompression-derived fat tissue, and the effects of dendrobine were studied in transforming growth factor-beta 1 (TGF-β1)-induced fibrosis models and interleukin-1β (IL-1β)-induced inflammation models. The results showed that dendrobine inhibited the migration, fibrosis and levels of inflammatory factors in TAO OFs. Network pharmacology and transcriptomics studies revealed the mechanisms of dendrobine, while in vitro experiments confirmed it alleviates TGF-β1-induced fibrosis in TAO OFs by inhibiting AKT phosphorylation.
Keywords: AKT; Dendrobine; Fibrosis; Molecular docking; Network pharmacology; Thyroid-associated ophthalmopathy; Transcriptomics.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Epac1 Inhibits Orbital Fibroblast Activation to Ameliorate Thyroid-Associated Orbitopathy-Like Features Through the JAK/STAT Signaling Pathway.Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):68. doi: 10.1167/iovs.66.9.68. Invest Ophthalmol Vis Sci. 2025. PMID: 40736178 Free PMC article.
-
CD34+ Orbital Fibroblasts Contribute to the Pathogenesis of Thyroid Eye Disease via miR-182-5p.J Clin Endocrinol Metab. 2025 Aug 7;110(9):2631-2644. doi: 10.1210/clinem/dgae876. J Clin Endocrinol Metab. 2025. PMID: 39693241
-
Cigarette Smoking Drives Thyroid Eye Disease Progression via RAGE Signaling Activation.Thyroid. 2025 Jul;35(7):803-815. doi: 10.1089/thy.2025.0062. Epub 2025 Jun 12. Thyroid. 2025. PMID: 40501349
-
Rituximab for thyroid-associated ophthalmopathy.Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD009226. doi: 10.1002/14651858.CD009226.pub3. Cochrane Database Syst Rev. 2022. PMID: 35709102 Free PMC article.
-
Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.BMC Ophthalmol. 2018 Feb 17;18(1):46. doi: 10.1186/s12886-018-0679-4. BMC Ophthalmol. 2018. PMID: 29452583 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources